{"filing":{"accession_number":"0001628280-26-048158","cik":"0000010456","ticker":"BAX","company_name":"BAXTER INTERNATIONAL INC","form":"8-K","filing_date":"2026-07-14","report_date":null,"primary_document":"bax-20260714.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/10456/000162828026048158/bax-20260714.htm"},"events":[{"id":17867,"run_id":16027,"accession_number":"0001628280-26-048158","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Baxter disclosed a material reorganization of its reportable segments effective Q2 2026, consolidating from three segments (Medical Products \u0026 Therapies, Healthcare Systems \u0026 Technologies, Pharmaceuticals) to two (MPT and HST), with the former Pharmaceuticals segment now nested within MPT's Infusion Therapies \u0026 Platforms division. The company also updated corporate cost allocation methodology. While the filing explicitly states this does not constitute a restatement and does not affect consolidated net income, EPS, total assets, or stockholders' equity, the segment restructuring reflects a fundamental change in how the chief operating decision maker allocates resources and assesses performance—a material operational and strategic realignment that would affect investor analysis of business performance and comparability across periods.","company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","filing_date":"2026-07-14","form":"8-K","submitted_at":null,"items":[{"id":16493,"accession_number":"0001628280-26-048158","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Baxter disclosed a material reorganization of its reportable segments effective Q2 2026, consolidating from three segments (Medical Products \u0026 Therapies, Healthcare Systems \u0026 Technologies, Pharmaceuticals) to two (MPT and HST), with the former Pharmaceuticals segment now nested within MPT's Infusion Therapies \u0026 Platforms division. The company also updated corporate cost allocation methodology. While the filing explicitly states this does not constitute a restatement and does not affect consolidated net income, EPS, total assets, or stockholders' equity, the segment restructuring reflects a fundamental change in how the chief operating decision maker allocates resources and assesses performance—a material operational and strategic realignment that would affect investor analysis of business performance and comparability across periods.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T20:16:59.667250+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16493,"accession_number":"0001628280-26-048158","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Baxter disclosed a material reorganization of its reportable segments effective Q2 2026, consolidating from three segments (Medical Products \u0026 Therapies, Healthcare Systems \u0026 Technologies, Pharmaceuticals) to two (MPT and HST), with the former Pharmaceuticals segment now nested within MPT's Infusion Therapies \u0026 Platforms division. The company also updated corporate cost allocation methodology. While the filing explicitly states this does not constitute a restatement and does not affect consolidated net income, EPS, total assets, or stockholders' equity, the segment restructuring reflects a fundamental change in how the chief operating decision maker allocates resources and assesses performance—a material operational and strategic realignment that would affect investor analysis of business performance and comparability across periods.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T20:16:59.667250+00:00","company_name":"BAXTER INTERNATIONAL INC","ticker":"BAX","filing_date":"2026-07-14"}]}